X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, First Wave will advance its lead product candidate IMGX003 (latiglutenase) for research & development and commercialization purposes. Currently, it is being evaluated in Phase II clinical trial studies for the treatment of Celiac disease.
Lead Product(s): Latiglutenase
Therapeutic Area: Gastroenterology Product Name: IMGX003
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: First Wave BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 14, 2024
Details:
Through the acquisition, First Wave will advance its lead product candidate IMGX003 (latiglutenase) for research & development and commercialization purposes. Currently, it is being evaluated in Phase II clinical trial studies for the treatment of Celiac disease.
Lead Product(s): Latiglutenase
Therapeutic Area: Gastroenterology Product Name: IMGX003
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: First Wave BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 18, 2023
Details:
The company is developing latiglutenase (IMGX003) for celiac disease therapy. ImmunogenX is also developing a diagnostic tool for celiac disease management as a minimally-invasive monitor of villus health to follow the state of recovery of a celiac patient.
Lead Product(s): Latiglutenase
Therapeutic Area: Gastroenterology Product Name: IMGX003
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mayo Clinic
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2022
Details:
CeliacShield Trial is a double-blind, placebo controlled, gluten challenge trial of the efficacy, safety and tolerability of 6-weeks treatment of Latiglutenase (IMGX003) administration in patients with well-controlled celiac disease.
Lead Product(s): Latiglutenase
Therapeutic Area: Immunology Product Name: IMGX003
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2021
Details:
The trial will test the safety and efficacy of the company’s lead therapeutic candidate, Latiglutenase (IMGX003).
Lead Product(s): Latiglutenase
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
